Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher's disease

ChemBioChem

Volumn 7, Issue 9, 2006, Pages 1356-1359

  Compain, Philippe ^a   Martin, Olivier R ^a   Boucheron, Charlotte ^a   Godin, Guillaume ^a   Yu, Liang ^b   Ikeda, Kyoko ^b   Asano, Naoki ^b  

^a UNIVERSITÉ D'ORLÉANS   (France)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

Chemical chaperones; Drug design; Enzymes; Gaucher's disease; Iminosugar; Inhibitors

Indexed keywords

1 DEOXYNOJIRIMYCIN; 1,5 DIDEOXY 1,5 IMINO DEXTRO XYLITOL; ALPHA 1 C ALKYL 1 DEOXYNOJIRIMYCIN; ALPHA 1 C ALKYL 1 DEOXYNOJIRIMYCIN DERIVATIVE; ALPHA 1 C NONYL 1 DEOXYNOJIRIMYCIN; ALPHA GALACTOSIDASE; AMINOXYLOSE DERIVATIVE; CHAPERONE; ENZYME INHIBITOR; GLUCOSYLCERAMIDASE; GLYCOSIDASE; GLYCOSIDASE INHIBITOR; GLYCOSPHINGOLIPID; IMIGLUCERASE; IMINE; IMINOXYLITOL DERIVATIVE; MIGLUSTAT; N BUTYL DEOXYNOJIRIMYCIN 1; N NONYL 1 DEOXYNOJIRIMYCIN; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; XYLITOL; XYLOSE;

ABDOMINAL PAIN; ARTICLE; CLINICAL FEATURE; DOSE RESPONSE; DRUG DESIGN; DRUG RESEARCH; ENZYME DEFICIENCY; ENZYME INHIBITION; ENZYME REPLACEMENT; FIBROBLAST; GAUCHER DISEASE; HUMAN; LYSOSOME STORAGE DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SYMPTOMATOLOGY; SYNTHESIS; WEIGHT REDUCTION;

1-DEOXYNOJIRIMYCIN; CATALYSIS; DRUG DESIGN; ENZYME INHIBITORS; FIBROBLASTS; GAUCHER DISEASE; GLUCAN 1,4-ALPHA-GLUCOSIDASE; GLUCOSIDASES; GLUCOSYLCERAMIDASE; HUMANS; IMINES; XYLITOL;

EID: 33748556543     PISSN: 14394227     EISSN: 14397633     Source Type: Journal    
DOI: 10.1002/cbic.200600217     Document Type: Article

References (33)

1. T. Kolter, M. Wendeler, ChemBioChem 2003, 4, 260-264.
2. a) B. Winchester, A. Vellodi, E. Young, Biochem. Soc. Trans. 2000, 28, 150-154;
3. b) J. Rapola, Pathol. Res. Pract. 1994, 190, 759-766;
4. c) A special issue of Philosophical Transaction: Biological Sciences has been devoted to glycolipids in cell biology and medicine: Philos. Trans. R. Soc. London Ser. B 2003, 358, 845-983.
5. a) J.-Q. Fan, S. Ishii, N. Asano, Y. Suzuki, Nat. Med. 1999, 5, 112-115;
6. b) N. Asano, S. Ishii, H. Kizu, K. Ikeda, K. Yasuda, A. Kato, O. R. Martin, J.-Q. Fan, Eur. J. Biochem. 2000, 267, 4179-4186;
7. c) S. Ishii, R. Kase, H. Sakuraba, Y. Suzuki, Biochem. Biophys. Res. Commun. 1993, 197, 1585-1589;
8. d) J.-Q. Fan, Trends Pharmacol. Sci. 2003, 24, 355-360.
9. G. H.-F. Yam, C. Zuber, J. Roth, FASEB J. 2005, 19, 12-18.
10. a) E. Conzelmann, K. Sandhoff, Dev. Neurosci. 1983/84, 6, 58-71;
11. b) P. Leinekugel, S. Michel, E. Conzelmann, K. Sandhoff, Hum. Genet. 1992, 88, 513-523.
12. a) A. R. Sawkar, W.-C. Cheng, E. Beutler, C.-H. Wong, W. E. Balch, J. W. Kelly, Proc. Natl. Acad. Sci. USA 2002, 99, 15428-15433;
13. b) H. Lin, Y. Sugimoto, Y. Ohsaki, H. Ninomiya, A. Oka, M. Taniguchi, H. Ida, Y. Eto, S. Ogawa, Y. Matsuzaki, M. Sawa, T. Inoue, K. Higaki, E. Nanba, K. Ohno, Y. Suzuki, Biochim. Biophys. Acta 2004, 1689, 219-228;
14. c) R. Lysek, C. Schütz, P. Vogel, Bioorg. Med. Chem. Lett. 2005, 15, 3071-3075.
15. The chemical-chaperone concept has been applied recently to other lysosomal diseases. See, for example: a) M. B. Tropak, S. P. Reid, M. Guiral, S. G. Withers, D. Mahuran, J. Biol. Chem. 2004, 279, 13478-13487;
16. b) J. Matsuda, O. Suziki, A. Oshima, Y. Yamamoto, A. Noguchi, K. Takimoto, M. Itoh, Y. Matsuzaki, Y. Yasuda, S. Ogawa, Y. Sakata, E. Nanba, K. Higaki, Y. Ogawa, L. Tominaga, K. Ohno, H. Iwasaki, H. Watanabe, R. O. Brady, Y. Suzuki, Proc. Natl. Acad. Sci. USA 2003, 100, 15912-15917.
17. Gaucher's Disease (Ed.: A. Zimran), Balliere Tindall, London, 1997.
18. A. H. Futerman, J. L. Sussman, M. Horowitz, I. Silman, A. Zimran, Trends Pharmacol. Sci. 2004, 25, 147-151.
19. a) T. Cox, R. Lachmann, C. Hollak, J. Aerts, S. van Weely, M. Hrebicek, F. M. Platt, T. Butters, R. Dwek, C. Moyses, I. Gow, D. Elstein, A. Zimran, Lancet 2000, 355, 1481-1485;
20. b) T. D. Butters, R. A. Dwek, P. M. Platt, Chem. Rev. 2000, 100, 4683-4696;
21. c) T. D. Butters, R. A. Dwek, F. M. Platt, Curr. Top. Med. Chem. 2003, 3, 561-574.
22. a) H. R. Mellor, F. M. Platt, R. A. Dwek, T. D. Butters, Biochem. J. 2003, 374, 307-314;
23. b) H. R. Mellor, J. Nolan, L. Pickering, M. R. Wormald, F. M. Platt, R. A. Dwek, G. W. J. Fleet, T. D. Butters, Biochem. J. 2002, 366, 225-233.
24. For selected references see: a) G. Godin, P. Compain, G. Masson, O. R. Martin, J. Org. Chem. 2002, 67, 6960-6970;
25. b) G. Godin, P. Compain, O. R. Martin, Org. Lett. 2003, 5, 3269-3272;
26. c) C. Boucheron, V. Desvergnes, P. Compain, O. R. Martin, A. Lavi, M. Mackeen, M. R. Wormald, R. A. Dwek, T. D. Butters, Tetrahedron: Asymmetry 2005, 16, 1747-1756.
27. G. Godin, P. Compain, O. R. Martin, K. Ikeda, L. Yu, N. Asano, Bioorg. Med. Chem. Lett. 2004, 14, 5991-5995.
28. DIX does not display any significant inhibitory activity against the following enzymes: yeast and rice a-glucosidases, almond β-glucosidases, human lysosomal α-glucosidase and rat intestinal isomaltase, sucrase and maltase.
29. A. Bordier, P. Compain, O. R. Martin, K. Ikeda, N. Asano, Tetrahedron: Asymmetry 2003, 14, 47-51.
30. The low yields observed for the one-pot procedure to give 10 may be explained by the relative instability of the intermediate aldehyde or of the related cyclic hemiaminal under aqueous acidic conditions (see refs. [12a] and [15]). In sharp contrast to our findings in the sorbofuranose series, attempts to optimize the process have not been successful to date.
31. 50 = 0.6 nM): X. Zhu, K. A. Sheth, S. Li, H.-H. Chang, J.-Q. Fan, Angew. Chem. 2005, 117, 7616-7619;
32. Angew. Chem. Int. Ed. 2005, 44, 7450-7453.
33. [17]